EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

The Assessment of Multidimensional Clinical, Biological and Patient-Reported Outcomes to Evaluate the Efficacy of Add-On Lactobacillus rhamnosus GG Supplementation in Mild Ulcerative Colitis: A Randomized Pilot Trial

Paola Maragno iD, Chiara Amoroso iD, Simone Conforti iD, Marco Michelon iD, Ivanna Honcharyuk iD, Clorinda Ciafardini, Daniele Noviello iD, Francesco Strati iD, Flavio Caprioli iD, Federica Facciotti iD, Maurizio Vecchi iD

Nutrients · 23.04.2026 · 18 (9) · 1329

DOI: 10.3390/nu18091329 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 23.04.2026. Verfasst von Paola Maragno und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. Hauptthemen laut MEDLINE: Lacticaseibacillus rhamnosus, Colitis, Ulcerative, Probiotics, Dietary Supplements. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ulcerative colitis (UC) is a multifactorial disease characterized by aberrant mucosal immune activation in response to intestinal dysbiosis. Contemporary management strategies aim to target inflammation and microbiome alterations while reducing relapse risk. A multidimensional assessment integrating clinical, inflammatory, immune, and microbial endpoints may better capture therapeutic effects beyond symptom control.

Aims

To evaluate whether supplementation with Lactobacillus rhamnosus GG co-formulated with vitamin D3 (Dicoflor IBD Immuno) as an adjunct to optimized mesalamine (5-ASA) is associated with coordinated changes across clinical and biological domains in mild-to-moderate UC, using a multidimensional assessment framework.

Methods

This single-center, randomized, double-blind, placebo-controlled pilot trial was conducted at Fondazione Ca’ Granda IRCCS Policlinico di Milano between May 2022 and May 2024. Thirty-six patients with mild-to-moderate UC receiving optimized 5-ASA were randomized to LGG+VitD3 (ALD3) or placebo (AP) for 4 weeks. Clinical activity, health-related quality of life (HRQoL), fecal calprotectin, peripheral immune cell subsets, and gut microbiota composition were assessed at baseline and week 4.

Results

Both 5-ASA-LGG+VitD3 (ALD3)- and 5-ASA-placebo (AP)-treated patients showed significant improvement in clinical activity and HRQoL, without between-group differences. A higher proportion of clinical responders was observed in the ALD3 group, although this was not statistically significant. LGG+VitD3-supplemented patients showed reduced fecal calprotectin levels and increased frequencies of IL-22-producing CD4+ T cells. Microbiome analysis revealed enrichment of short-chain fatty acid-producing taxa, including Coprococcus and Fusicatenibacter, in ALD3-treated patients.

Conclusions

In patients with mild UC receiving optimized 5-ASA, LGG+VitD3 supplementation does not improve short-term clinical outcomes beyond placebo but is associated with favorable modulation of inflammatory, immune, and microbial parameters, supporting the relevance of multidimensional biological endpoints in adjunctive UC management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lacticaseibacillus rhamnosusColitis, UlcerativeProbioticsDietary SupplementsHumansPilot ProjectsFemaleDouble-Blind MethodMaleAdultMesalamineMiddle AgedTreatment OutcomeQuality of LifeFecesCholecalciferolLeukocyte L1 Antigen ComplexGastrointestinal Microbiome

Stichwörter der Autor:innen

Lactobacillus rhamnosus GGadjunct therapyfecal calprotectinulcerative colitis

Substanzen

MesalamineCholecalciferolLeukocyte L1 Antigen Complex

Autor:innen und Institutionen

  • Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
  • Department of Pathophysiology and Transplantation, Università degli Studi di Milano, 20122 Milan, Italy.
  • Institute for Digestive Research, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
  • Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.

ORCID-Profile: Paola Maragno, Chiara Amoroso, Simone Conforti, Marco Michelon, Ivanna Honcharyuk, Daniele Noviello, Francesco Strati, Flavio Caprioli, Federica Facciotti, Maurizio Vecchi

Zitieren

APA

Maragno, P., Amoroso, C., Conforti, S., Michelon, M., Honcharyuk, I., Ciafardini, C., Noviello, D., Strati, F., Caprioli, F., Facciotti, F., & Vecchi, M. (2026). The Assessment of Multidimensional Clinical, Biological and Patient-Reported Outcomes to Evaluate the Efficacy of Add-On Lactobacillus rhamnosus GG Supplementation in Mild Ulcerative Colitis: A Randomized Pilot Trial. Nutrients, 18(9), 1329. https://doi.org/10.3390/nu18091329

Vancouver

Maragno P, Amoroso C, Conforti S, Michelon M, Honcharyuk I, Ciafardini C, et al. The Assessment of Multidimensional Clinical, Biological and Patient-Reported Outcomes to Evaluate the Efficacy of Add-On Lactobacillus rhamnosus GG Supplementation in Mild Ulcerative Colitis: A Randomized Pilot Trial. Nutrients. 2026;18(9):1329. doi:10.3390/nu18091329

BibTeX
@article{Maragno2026,
  author = {Maragno, Paola and Amoroso, Chiara and Conforti, Simone and Michelon, Marco and Honcharyuk, Ivanna and Ciafardini, Clorinda and Noviello, Daniele and Strati, Francesco and Caprioli, Flavio and Facciotti, Federica and Vecchi, Maurizio},
  title = {The Assessment of Multidimensional Clinical, Biological and Patient-Reported Outcomes to Evaluate the Efficacy of Add-On Lactobacillus rhamnosus GG Supplementation in Mild Ulcerative Colitis: A Randomized Pilot Trial},
  journal = {Nutrients},
  year = {2026},
  volume = {18},
  number = {9},
  pages = {1329},
  doi = {10.3390/nu18091329}
}
Kostenlos starten →